| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Indoleamine 2,3-dioxygenase (IDO), a key enzyme of tryptophan (Trp) metabolism, is involved in tumor-derived immune suppression by depleting Trp and accumulating the metabolite. We have recently shown that IDO expression was markedly increased in human glioblastoma and secondary glioblastoma with malignant change. The aim of this study is to investigate anti-tumor effect of IDO inhibition and to search the synergistic function of IDO inhibitor (1-MT) and temozolomide in a murine glioma model. In subcutaneous model, oral administration of 1-MT significantly suppressed tumor growth and synergistic anti-tumor effects of 1-MT and temozolomide were observed (P<0.01). The mice intracranially inoculated IDO knockdown cells had a significantly longer survival compared to the control mice (P<0.01). The mice intracranially inoculated IDO knockdown cells had a significantly longer survival compared to the control mice (P<0.01).
|
